TNF and ankylosing spondylitis: Another study on pamidronate (another intravenous bisphosphonate) vs golimumab (a TNF inhibitor approved for the treatment of SpA) showed similar improvements in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in the two groups, but with improvement in the Bath Ankylosing Spondylitis Functional Index (BASFI) and on MRI data on axial inflammation (evaluated according to Spondyloarthritis Research Consortium of Canada scoring system) being limited to the golimumab group [125].